Funding for this research was provided by:
Instituto Nacional del Cáncer, Ministerio de Salud de la República Argentina (Res. 0515)
Received: 9 March 2018
Accepted: 30 July 2018
First Online: 13 August 2018
Ethics approval and consent to participate
: Routine procedure included signing a written informed consent to genetic testing (including anonymized disclosure of the data) from each patient, approved by the Ethics Committee from CEMIC and a Pretest Counseling for Susceptibility Testing (purpose of testing), as described in the American Society of Clinical Oncology Policy Statement Update.
: SG is the medical director in AstraZeneca Argentina and Uruguay MC. LS is the diagnosis manager in AstraZeneca Argentina MC. IDP is the oncology medical manager in AstraZeneca Argentina and Uruguay MC. The other authors declare that they have no competing interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.